Healthcare provider profile · identity verified

Catherine Julee Whitlach, MD

Family Practice · TULARE, CA · NPI 1386272391

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	258	90
Losartan Potassium	Losartan Potassium	232	87
Amlodipine Besylate	Amlodipine Besylate	224	81
Levothyroxine Sodium	Levothyroxine Sodium	224	86
Omeprazole	Omeprazole	208	76
Lisinopril	Lisinopril	195	74
Metoprolol Succinate	Metoprolol Succinate	162	51
Gabapentin	Gabapentin	137	48
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	127	19
Metformin Hcl	Metformin Hcl	99	35
Trazodone Hcl	Trazodone Hcl	99	44
Glipizide	Glipizide	88	27
Potassium Chloride	Potassium Chloride	88	27
Albuterol Sulfate Hfa	Albuterol Sulfate	87	39
Fluticasone Propionate	Fluticasone Propionate	81	34
Rosuvastatin Calcium	Rosuvastatin Calcium	81	32
Carvedilol	Carvedilol	79	26
Furosemide	Furosemide	73	29
Duloxetine Hcl	Duloxetine Hcl	70	25
Eliquis	Apixaban	69	27
Metformin Hcl Er	Metformin Hcl	67	27
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	63	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	62	27
Pantoprazole Sodium	Pantoprazole Sodium	59	23
Tamsulosin Hcl	Tamsulosin Hcl	59	23
Sertraline Hcl	Sertraline Hcl	58	22
Tramadol Hcl	Tramadol Hcl	56	12
Pravastatin Sodium	Pravastatin Sodium	52	13
Citalopram Hbr	Citalopram Hydrobromide	49	17
Oxycodone Hcl	Oxycodone Hcl	46	17
Quetiapine Fumarate	Quetiapine Fumarate	46	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	45	19
Ozempic	Semaglutide	44	suppressed
Tizanidine Hcl	Tizanidine Hcl	44	18
Simvastatin	Simvastatin	43	19
Warfarin Sodium	Warfarin Sodium	43	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	40	12
Jardiance	Empagliflozin	38	12
Mirtazapine	Mirtazapine	38	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	36	16
Ipratropium Bromide	Ipratropium Bromide	35	12
Fluoxetine Hcl	Fluoxetine Hcl	34	11
Metoprolol Tartrate	Metoprolol Tartrate	34	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	33	20
Montelukast Sodium	Montelukast Sodium	32	12
Ondansetron Odt	Ondansetron	32	16
Ropinirole Hcl	Ropinirole Hcl	31	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	31	22
Clopidogrel	Clopidogrel Bisulfate	30	11
Fenofibrate	Fenofibrate Nanocrystallized	29	suppressed
Allopurinol	Allopurinol	28	12
Breo Ellipta	Fluticasone/Vilanterol	28	suppressed
Loperamide	Loperamide Hcl	28	18
Meloxicam	Meloxicam	28	12
Ventolin Hfa	Albuterol Sulfate	28	suppressed
Divalproex Sodium	Divalproex Sodium	27	suppressed
Bupropion Xl	Bupropion Hcl	26	12
Advair Hfa	Fluticasone Propion/Salmeterol	25	suppressed
Cephalexin	Cephalexin	25	suppressed
Famotidine	Famotidine	25	suppressed
Alprazolam	Alprazolam	23	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Celecoxib	Celecoxib	22	11
Chlorthalidone	Chlorthalidone	22	suppressed
Naproxen	Naproxen	22	suppressed
Pregabalin	Pregabalin	22	suppressed
Tresiba Flextouch U-100	Insulin Degludec	22	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Nystatin	Nystatin	21	suppressed
Torsemide	Torsemide	21	suppressed
Alendronate Sodium	Alendronate Sodium	20	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	20	suppressed
Baclofen	Baclofen	19	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	18	suppressed
Clonidine Hcl	Clonidine Hcl	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Hydrocortisone	Hydrocortisone	18	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Glipizide Er	Glipizide	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Aripiprazole	Aripiprazole	16	suppressed
Acyclovir	Acyclovir	15	suppressed
Atenolol	Atenolol	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Lidocaine	Lidocaine	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Levetiracetam	Levetiracetam	14	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	14	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Synthroid	Levothyroxine Sodium	14	suppressed
Olanzapine Odt	Olanzapine	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Glimepiride	Glimepiride	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	12	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	11	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	11	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Ethacrynic Acid	Ethacrynic Acid	11	suppressed
Finasteride	Finasteride	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Spironolactone	Spironolactone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error